- Conditions
- Alcohol Associated Hepatitis
- Interventions
- INT-787, Placebo
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 20
- States / cities
- Fresno, California • Palo Alto, California • Sacramento, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 13,796
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 994 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 42
- States / cities
- Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
- Conditions
- Peripheral Artery Disease, Peripheral Artery Stenosis, Peripheral Artery Calcification, PAD
- Interventions
- Thor laser atherectomy
- Device
- Lead sponsor
- Philips Clinical & Medical Affairs Global
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 29
- States / cities
- St. Helena, California • Aurora, Colorado • Bradenton, Florida + 24 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- brentuximab vedotin, doxorubicin, bleomycin, vinblastine, dacarbazine
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 80 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
- Interventions
- CG-806
- Drug
- Lead sponsor
- Aptose Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 30
- States / cities
- Los Angeles, California • Monterey, California • Redondo Beach, California + 25 more
- Conditions
- HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor, Advanced Solid Tumors, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreatic Cancer, Melanoma
- Interventions
- FATE-NK100, Cetuximab, Trastuzumab
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- San Diego, California • Minneapolis, Minnesota • Columbus, Ohio + 1 more
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Adalimumab, CP-690,550, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 22
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • Northridge, California + 17 more
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- Rasagiline, Placebo
- Drug
- Lead sponsor
- Richard Barohn, MD
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Irvine, California • San Francisco, California + 7 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- warfarin, placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more
- Conditions
- Leukemia, Myeloid, Chronic Phase
- Interventions
- Imatinib mesylate
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 476 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 50
- States / cities
- Mobile, Alabama • Berkeley, California • Campbell, California + 35 more
- Conditions
- Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
- Interventions
- ADI-001
- Genetic
- Lead sponsor
- Adicet Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2039
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Louisville, Kentucky • Dallas, Texas + 2 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Filgotinib, Placebo to match filgotinib
- Drug
- Lead sponsor
- Alfasigma S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 72
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more
- Conditions
- Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, SPG4, SPG5A, Spastic Paraplegia 4, Spastic Paraplegia 5A, Early Onset Hereditary Spastic Paraplegia, Neuromuscular Diseases, Spastic Paraplegia, Hereditary
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- Miami, Florida • Iowa City, Iowa • Boston, Massachusetts + 6 more
- Conditions
- Hemophilia A, Severe Hemophilia A
- Interventions
- rVIII-SingleChain
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- Male only
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 9
- States / cities
- San Diego, California • Aurora, Colorado • Hartford, Connecticut + 6 more
- Conditions
- Plaque Psoriasis, Skin Diseases
- Interventions
- JTE-051, Placebo
- Drug
- Lead sponsor
- Shionogi Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 12
- States / cities
- Fountain Valley, California • Fremont, California • Tampa, Florida + 9 more
- Conditions
- Non Small Cell Lung Cancer, KRAS Activating Mutation
- Interventions
- avutometinib and sotorasib, avutometinib and sotorasib and defactinib
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 20
- States / cities
- Boulder, Colorado • Washington D.C., District of Columbia • Arlington Heights, Illinois + 16 more
- Conditions
- Parkinson's Disease
- Interventions
- Prasinezumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 47 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Cilofexor, Placebo to match cilofexor
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 16
- States / cities
- Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more
- Conditions
- Traumatic Brain Injury
- Interventions
- Transcranial direct current stimulation, sham tDCS
- Device
- Lead sponsor
- The University of Texas at Dallas
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Prostate Cancer
- Interventions
- Dexamethasone, Prednisone, docetaxel, Oral antiandrogen, Radiation therapy, LHRH agonist
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 612 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2022
- U.S. locations
- 245
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 194 more
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Interventions
- Angel® Catheter
- Device
- Lead sponsor
- BiO2 Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Jackson, Mississippi • Portland, Oregon • Dallas, Texas + 1 more
- Conditions
- Desaturation of Blood, Obesity, Colonoscopy, Sleep Apnea, High Flow Nasal Cannula
- Interventions
- The Comfort Flo system, The Salter nasal cannula
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Dyslipidemia
- Interventions
- Muraglitazar
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002
- U.S. locations
- 53
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Irvine, California + 50 more
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Active rTMS, Sham rTMS, Cognitive Processing Therapy
- Device · Behavioral
- Lead sponsor
- The University of Texas at Dallas
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 3
- States / cities
- Tallahassee, Florida • Addison, Texas • Dallas, Texas